title: Considerations for characterizing the risk of PML in natalizumab-treated patients.
authors.affiliation: Biogen, Landis & Gyr Strasse 3, Zug, 6300 Switzerland. Electronic address: harold.koendgen@biogen.com.
authors.forename: Harold
authors.initials: H
authors.lastname: Koendgen
authors.affiliation: Biogen, 225 Binney Street, Cambridge, MA, 02142 USA.
authors.forename: Pei-Ran
authors.initials: PR
authors.lastname: Ho
authors.affiliation: Biogen, 225 Binney Street, Cambridge, MA, 02142 USA.
authors.forename: Ih
authors.initials: I
authors.lastname: Chang
mesh_terms: D000465:Algorithms; D000914:Antibodies, Viral / Q000097:blood; D000068456:Clinical Studies as Topic; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects* / Q000627:therapeutic use; D007577:JC Virus / Q000276:immunology; D007968:Leukoencephalopathy, Progressive Multifocal / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology* / Q000276:immunology; D000069442:Natalizumab / Q000009:adverse effects* / Q000627:therapeutic use; D018570:Risk Assessment
chemical_list: D000914:Antibodies, Viral; D007155:Immunologic Factors; D000069442:Natalizumab